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Background
The etiology of lupus erythematosus (LE) is not eluci-
dated, but the impact of non-genetic factors is unques-
tionable. Smoking as a life style is often linked to
development of autoimmune diseases, such as LE.
Furthermore, it is generally considered that smokers have
higher disease activity compared to nonsmokers and ex-
smokers, as well as poorer response to standard therapy.
Main aims of our study were to determine differences in
disease activity and therapeutic response between smo-
kers and nonsmokers in a group of patients with cuta-
neous and systemic lupus, as well as to compare smoking
prevalence among our patients and general population.
Methods
The study was conducted among 65 patients (14 male,
51 female) in the database of Clinic for Dermatovener-
eology, Clinical Centre of Serbia (42 with cutaneous LE,
23 with systemic LE). Smoking status data was obtained
by telephone survey. We analyzed the following criteria:
smoking prevalence among patients compared to gen-
eral population, pack-years parameter and the disease
activity indices - SLEDAI-2K, ACR/SLICC, CLASI and
rCLASI. We also analyzed patients’ status on the follow-
up visit, defined as \“improvement”, \“deterioration\” or
\“without significant change\”. As for statistical methods
we used the independent samples t-test in order to
determine difference between these parameters among
smokers and nonsmokers.
Results
Smoking was by far more common among our patients
(74%) than in general population of Serbia (27%) [6]. All
activity and damage parameters were higher among
smokers; for rCLASI A parameter the difference was
statistically significant (p<0.05). Furthermore, patients
with higher pack-years parameter also showed higher
SLEDAI-2K score. Finally, smokers had poorer thera-
peutic response compared to nonsmokers on the follow-
up visit (50% of non-smokers showed improvement,
compared to 38% of smokers).
Conclusions
Our results are in accordance with the hypothesis that
smoking may have an unfavorable impact on develop-
ment, activity and treatment of lupus.
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